Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

Andrew D Althouse, J Dawn Abbott, Kim Sutton-Tyrrell, Alan D Forker, Manuel S Lombardero, L Virginia Buitrón, Ivan Pena-Sing, Jean-Claude Tardif, Maria Mori Brooks, BARI 2D Study Group, Andrew D Althouse, J Dawn Abbott, Kim Sutton-Tyrrell, Alan D Forker, Manuel S Lombardero, L Virginia Buitrón, Ivan Pena-Sing, Jean-Claude Tardif, Maria Mori Brooks, BARI 2D Study Group

Abstract

Objective: The aim of this manuscript was to report the risk of incident peripheral arterial disease (PAD) in a large randomized clinical trial that enrolled participants with stable coronary artery disease and type 2 diabetes and compare the risk between assigned treatment arms.

Research design and methods: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomly assigned participants to insulin sensitization (IS) therapy versus insulin-providing (IP) therapy for glycemic control. Results showed similar 5-year mortality in the two glycemic treatment arms. In secondary analyses reported here, we examine the effects of treatment assignment on the incidence of PAD. A total of 1,479 BARI 2D participants with normal ankle-brachial index (ABI) (0.91-1.30) were eligible for analysis. The following PAD-related outcomes are evaluated in this article: new low ABI≤0.9, a lower-extremity revascularization, lower-extremity amputation, and a composite of the three outcomes.

Results: During an average 4.6 years of follow-up, 303 participants experienced one or more of the outcomes listed above. Incidence of the composite outcome was significantly lower among participants assigned to IS therapy than those assigned to IP therapy (16.9 vs. 24.1%; P<0.001). The difference was significant in time-to-event analysis (hazard ratio 0.66 [95% CI 0.51-0.83], P<0.001) and remained significant after adjustment for in-trial HbA1c (0.76 [0.59-0.96], P=0.02).

Conclusions: In participants with type 2 diabetes who are free from PAD, a glycemic control strategy of insulin sensitization may be the preferred therapeutic strategy to reduce the incidence of PAD and subsequent outcomes.

Trial registration: ClinicalTrials.gov NCT00006305.

Figures

Figure 1
Figure 1
Flowchart of ABI measurements available in all BARI 2D patients (N = 2,368). Revasc, revascularization.
Figure 2
Figure 2
Cumulative incidence of PAD and related outcomes by assigned glycemic control strategy.

References

    1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738–743
    1. Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med 2007;32:328–333
    1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381–386
    1. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993;270:487–489
    1. O’Hare AM, Katz R, Shlipak MG, Cushman M, Newman AB. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006;113:388–393
    1. Sutton-Tyrrell K, Venkitachalam L, Kanaya AM, et al. Relationship of ankle blood pressures to cardiovascular events in older adults. Stroke 2008;39:863–869
    1. Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008;52:1736–1742
    1. Criqui MH, McClelland RL, McDermott MM, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010;56:1506–1512
    1. American Diabetes Association Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333–3341
    1. Palumbo PJ, O’Fallon WM, Osmundson PJ, Zimmerman BR, Langworthy AL, Kazmier FJ. Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive? Arch Intern Med 1991;151:717–721
    1. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433–1437
    1. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002;25:113–120
    1. Brach JS, Solomon C, Naydeck BL, et al. Cardiovascular Health Study Research Group Incident physical disability in people with lower extremity peripheral arterial disease: the role of cardiovascular disease. J Am Geriatr Soc 2008;56:1037–1044
    1. Adler AI, Boyko EJ, Ahroni JH, Smith DG. Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 1999;22:1029–1035
    1. Leibson CL, Ransom JE, Olson W, Zimmerman BR, O’fallon WM, Palumbo PJ. Peripheral arterial disease, diabetes, and mortality. Diabetes Care 2004;27:2843–2849
    1. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894–899
    1. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 2005;28:1981–1987
    1. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006;29:877–882
    1. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–431
    1. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes—a review. Diabet Med 2010;27:4–14
    1. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006;47:921–929
    1. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl. 1):S1–S75
    1. Frye RL, August P, Brooks MM, et al. BARI 2D Study Group A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–2515
    1. Brooks MM, Frye RL, Genuth S, et al. Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97(12A):9G–19G
    1. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J 2008; 156:528–536.e1-5
    1. Magee MF, Isley WL, BARI 2D Trial Investigators Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97(12A):20G–30G
    1. Singh PP, Abbott JD, Lombardero MS, et al. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 2011;34:464–467
    1. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L, PROactive investigators Impact of peripheral arterial disease in patients with diabetes—results from PROactive (PROactive 11). Atherosclerosis 2009;202:272–281
    1. Sobel BE, Hardison RM, Genuth S, et al. BARI 2D Investigators Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2011;124:695–703
    1. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139
    1. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
    1. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
    1. Patel CB, De Lemos JA, Wyne KL, McGuire DK. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar γ agonism. Diab Vasc Dis Res 2006;3:65–71
    1. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460–2470
    1. Yamasaki Y, Katakami N, Furukado S, et al. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb 2010;17:1132–1140
    1. Park YM, R Kashyap S, A Major J, Silverstein RL. Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis. Lab Invest 2012;92:1171–1180
    1. Rajamani K, Colman PG, Li LP, et al. FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780–1788
    1. Gandhi S, Weinberg I, Margey R, Jaff MR. Comprehensive medical management of peripheral arterial disease. Prog Cardiovasc Dis 2011;54:2–13
    1. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602–609
    1. Chi YW, Jaff MR. Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheter Cardiovasc Interv 2008;71:475–489

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する